Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025
Royalty Pharma (Nasdaq: RPRX) will report third quarter 2025 financial results on Wednesday, November 5, 2025 before U.S. markets open.
The company will host a conference call and simultaneous webcast on that day at 8:00 a.m. Eastern Time. Investors can obtain call details and view the live webcast on the company's Investors events page. A replay of the call and webcast will be archived on the website for at least 30 days.
Royalty Pharma (Nasdaq: RPRX) pubblicherà i risultati finanziari del terzo trimestre 2025 il mercoledì 5 novembre 2025 prima dell'apertura dei mercati statunitensi.
L'azienda terrà una conference call e una trasmissione web simultanea nello stesso giorno alle 8:00 ora della Eastern Time. Gli investitori possono ottenere i dettagli della chiamata e seguire la trasmissione in diretta sulla pagina Investors events dell'azienda. Una riproduzione della chiamata e della webcast sarà archiviata sul sito per almeno 30 giorni.
Royalty Pharma (Nasdaq: RPRX) reportará los resultados financieros del tercer trimestre de 2025 el miércoles 5 de noviembre de 2025 antes de la apertura de los mercados de EE. UU.
La empresa organizará una conferencia telefónica y una transmisión web simultánea ese día a las 8:00 a.m. hora del Este. Los inversionistas pueden obtener los detalles de la llamada y ver la transmisión en vivo en la página de eventos para inversores de la empresa. Una repetición de la llamada y del webcast estará archivada en el sitio durante al menos 30 días.
Royalty Pharma (Nasdaq: RPRX)는 2025년 3분기 재무 실적을 미국 시장 개장 전에 발표합니다.
회사는 같은 날 동부 표준시 기준 오전 8:00에 컨퍼런스 콜과 동시 생방송을 개최합니다. 투자자들은 회사의 Investors events 페이지에서 콜 세부 정보를 얻고 라이브 생중계를 시청할 수 있습니다. 콜과 생중계의 재생은 최소 30일 동안 웹사이트에 보관됩니다.
Royalty Pharma (Nasdaq: RPRX) publiera les résultats financiers du troisième trimestre 2025 le mercredi 5 novembre 2025 avant l'ouverture des marchés américains.
L'entreprise organisera une conférence téléphonique et une diffusion en direct simultanée ce jour-là à 8h00, heure de l'Est. Les investisseurs peuvent obtenir les détails de l'appel et voir la diffusion en direct sur la page Investors events de l'entreprise. Une rediffusion de l'appel et de la diffusion sera archivée sur le site pendant au moins 30 jours.
Royalty Pharma (Nasdaq: RPRX) wird die Finanzergebnisse für das dritte Quartal 2025 am Mittwoch, 5. November 2025 vor der US-Markteröffnung bekannt geben.
Das Unternehmen wird an diesem Tag eine Telefonkonferenz und eine gleichzeitige Webcast-Sitzung um 8:00 Uhr Eastern Time abhalten. Investoren erhalten die Anrufdetails und sehen den Live-Webcast auf der Unternehmensseite Investors events. Eine Wiedergabe des Anrufs und des Webcasts wird auf der Website mindestens 30 Tage lang archiviert.
Royalty Pharma (Nasdaq: RPRX) ستعلن عن نتائجها المالية للـ الربع الثالث من 2025 في الأربعاء 5 نوفمبر 2025 قبل فتح الأسواق الأمريكية.
ستستضيف الشركة مكالمة جماعية وبثًا حيًا متزامنًا في ذلك اليوم في 8:00 صباحًا بتوقيت شرق الولايات المتحدة. يمكن للمستثمرين الحصول على تفاصيل المكالمة وعرض البث المباشر على صفحة Investors events الخاصة بالشركة. ستُرشَح إعادة المكالمة والبث على الموقع لمدة لا تقل عن 30 يومًا.
Royalty Pharma (Nasdaq: RPRX) 将在美国市场开盘前公布 2025 年第 3 季度 财报，时间为 2025 年 11 月 5 日，星期三。
公司将在当天举行一场电话会议及同步网络直播，时间为 美国东部时间早上 8:00。投资者可以在公司的网站 Investors events 页面获取通话详情并观看实时网络直播。该通话与网络直播的重播将至少在网站上保存 30 天。
- None.
- None.
NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2025 financial results on Wednesday, November 5, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.
Conference Call Information
Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company's website for at least 30 days.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, Johnson & Johnson’s Tremfya, GSK’s Trelegy, Roche’s Evrysdi, Servier’s Voranigo, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 17 development-stage product candidates. For more information, visit www.royaltypharma.com.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6637
ir@royaltypharma.com
FAQ
When will Royalty Pharma (RPRX) report Q3 2025 results?
What time is the Royalty Pharma (RPRX) Q3 2025 earnings call?
Where can I find the Royalty Pharma (RPRX) webcast link for the November 5, 2025 call?
Will Royalty Pharma (RPRX) provide a replay of the Q3 2025 call?
Is the Royalty Pharma (RPRX) Q3 2025 report published before market open?
